PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016
DelveInsight Report, “PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016” gives the comprehensive insights on the PD-1 and PDl-1 Inhibitors. The report has provided the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors including information of Marketed molecules, detailed profiling of Pipeline assets and their pathways. The report has covered the therapeutics assessment of pipeline molecules by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates. Report is also dealing with detailed epidemiology of all prevalent indications.
Report has also covered other Commercial Aspects such as the Current and Future Market, Barriers and challenges, SWOT analysis. Report has described the unmet needs covered by PD-1 and PD-L1 inhibitors and highlighted the side effects and toxic effects related to PD-1 and PD-L1 inhibitors which are major concerns in the market for the usage of PD-1 and PD-L1 inhibitors.
The report has also thrown light on the combinations therapies with Immune-check point Inhibitors (PD-1 and PDL-1), provided the information of ongoing collaborations for the development of combinations regimens.
DelveInsight Analysis predicts that PD-1 and PD-L1 inhibitors are among the highly growing fields in biopharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. There are 51 drugs are in pipeline with approximate 245 active clinical studies. Companies have also gone in collaboration with different partners like Bristol, Merck, Astrazeneca and Roche for evaluating their drugs in combination with Immune Checkpoint Inhibitors (PD-1/PD-L1). There are total 37 companies found which have partnered with various Big Pharmas.
Out of 51 drugs, 44 drugs are in Monotherapy and 7 drugs are in the combination therapy. Out of 43 Monotherapy drugs, 2 is in Filed stage and 3 drugs are in phase III, 2 drug is in Phase II, 9 drugs are in Phase I, 19 drugs are in Pre-Clinical and 7 drugs are in discovery phase and 2 in Unknown stage. Out of 7 combination therapy drugs 2 are in Phase I, 2 are in Pre-Clinical stage of development and 3 are in Discovery stage.
Future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. There are 3 marketed products of PD-1 and PD-L1 inhibitors. Treatment options such as surgery, chemotherapy, radiation therapy, and many others are able to fulfill the current unmet need to an extent. The market for PD-1 and PD-L1 drugs might be billions of dollars in coming years. These drugs which include Bristol-Myers' Opdivo, Merck's Keytruda and Hoffmann-La Roche' Tecentriq are going to be the blockbuster molecules in upcoming years.
PD-1 and PD-L-1 inhibitors are showing greater efficacy as immune-therapeutic drugs but with the immune system unchecked, there is the possibility that immune cells attack other parts of the body, causing serious problems in the intestines, liver, nerves, eyes, or other organs. Although Preliminary data suggests that PD-1/PD-L1 immunotherapies provide faster and more frequent responses.